{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:44:56Z","timestamp":1784907896607,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00198-024-07139-9","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T16:03:48Z","timestamp":1717603428000},"page":"1669-1675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1242-2476","authenticated-orcid":false,"given":"Shejil","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti L.","family":"Gild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick J.","family":"Clifton-Bligh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"issue":"8","key":"7139_CR1","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354(8):821\u2013831. https:\/\/doi.org\/10.1056\/NEJMoa044459","journal-title":"N Engl J Med"},{"issue":"7","key":"7139_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513\u2013523. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"7139_CR3","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96(4):972\u2013980. https:\/\/doi.org\/10.1210\/jc.2010-1502","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"7139_CR4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","volume":"106","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab 106(1):264\u2013281. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"7139_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/jcm10010152","volume":"10","author":"AD Anastasilakis","year":"2021","unstructured":"Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A (2021) Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med 10(1):152. https:\/\/doi.org\/10.3390\/jcm10010152","journal-title":"J Clin Med"},{"issue":"16","key":"7139_CR6","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"issue":"15","key":"7139_CR7","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"issue":"6","key":"7139_CR8","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman F, Kendler DL, Langdahl BL et al (2022) Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int 33(6):1243\u20131256. https:\/\/doi.org\/10.1007\/s00198-021-06174-0","journal-title":"Osteoporos Int"},{"issue":"3","key":"7139_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","volume":"105","author":"D Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM et al (2020) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab 105(3):587\u2013594. https:\/\/doi.org\/10.1210\/clinem\/dgaa048","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"7139_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R et al (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30(1):3\u201344. https:\/\/doi.org\/10.1007\/s00198-018-4704-5","journal-title":"Osteoporos Int"},{"issue":"7","key":"7139_CR11","doi-asserted-by":"publisher","first-page":"e10512","DOI":"10.1002\/jbm4.10512","volume":"5","author":"MR McClung","year":"2021","unstructured":"McClung MR, Bolognese MA, Brown JP et al (2021) Skeletal responses to romosozumab after 12 months of denosumab. JBMR Plus 5(7):e10512. https:\/\/doi.org\/10.1002\/jbm4.10512","journal-title":"JBMR Plus"},{"issue":"6","key":"7139_CR12","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00198-021-06261-2","volume":"33","author":"A Tominaga","year":"2022","unstructured":"Tominaga A, Wada K, Okazaki K et al (2022) Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment. Osteoporos Int 33(6):1265\u20131273. https:\/\/doi.org\/10.1007\/s00198-021-06261-2","journal-title":"Osteoporos Int"},{"issue":"5","key":"7139_CR13","doi-asserted-by":"publisher","first-page":"105219","DOI":"10.1016\/j.jbspin.2021.105219","volume":"88","author":"K Ebina","year":"2021","unstructured":"Ebina K, Tsuboi H, Nagayama Y et al (2021) Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. Joint Bone Spine 88(5):105219. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105219","journal-title":"Joint Bone Spine"},{"key":"7139_CR14","doi-asserted-by":"crossref","unstructured":"Hong N, Shin S, Kim H, Rhee Y (2023) Romosozumab after denosumab improves lumbar spine bone mineral density and microarchitecture greater than denosumab continuation in postmenopausal women. Program of ENDO 2023, Chicago, IL (Abstract OR13\u201306)","DOI":"10.1210\/jendso\/bvad114.473"},{"key":"7139_CR15","doi-asserted-by":"publisher","first-page":"100288","DOI":"10.1016\/j.bonr.2020.100288","volume":"13","author":"M Kashii","year":"2020","unstructured":"Kashii M, Ebina K, Kitaguchi K, Yoshikawa H (2020) Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: a case report. Bone Rep 13:100288. https:\/\/doi.org\/10.1016\/j.bonr.2020.100288","journal-title":"Bone Rep"},{"issue":"4","key":"7139_CR16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s40265-019-01072-6","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A (2019) Romosozumab: first global approval. Drugs 79(4):471\u2013476. https:\/\/doi.org\/10.1007\/s40265-019-01072-6","journal-title":"Drugs"},{"issue":"1","key":"7139_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/8755122520967632","volume":"37","author":"SA Miller","year":"2021","unstructured":"Miller SA, St Onge EL, Whalen KL (2021) Romosozumab: a novel agent in the treatment for postmenopausal osteoporosis. J Pharm Technol 37(1):45\u201352. https:\/\/doi.org\/10.1177\/8755122520967632","journal-title":"J Pharm Technol"},{"issue":"9999","key":"7139_CR18","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386(9999):1147\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5","journal-title":"Lancet"},{"issue":"3","key":"7139_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00198-022-06651-0","volume":"34","author":"AS Solling","year":"2023","unstructured":"Solling AS, Harslof T, Jorgensen NR, Langdahl B (2023) Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption. Osteoporos Int 34(3):599\u2013605. https:\/\/doi.org\/10.1007\/s00198-022-06651-0","journal-title":"Osteoporos Int"},{"issue":"18","key":"7139_CR20","doi-asserted-by":"publisher","first-page":"167790","DOI":"10.1172\/jci.insight.167790","volume":"8","author":"Q Fu","year":"2023","unstructured":"Fu Q, Bustamante-Gomez NC, Reyes-Pardo H et al (2023) Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation. JCI Insight 8(18):167790. https:\/\/doi.org\/10.1172\/jci.insight.167790","journal-title":"JCI Insight"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07139-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-024-07139-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07139-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T04:03:00Z","timestamp":1724990580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-024-07139-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["7139"],"URL":"https:\/\/doi.org\/10.1007\/s00198-024-07139-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"10 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for retrospective review of data on patients presenting to osteoporosis and fracture prevention clinics at Westmead Hospital, Sydney, was obtained from the Western Sydney Local Health District (WSLHD) Human Research Ethics Committee (Protocol ID: 2101\u201312).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human rights"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}